Combined oral contraceptives and the risk of myocardial infarction

Annals of Medicine

Volumn 35, Issue 6, 2003, Pages 413-418

  Keeling, David ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Myocardial infarction; Oral contraceptives; Smoking

Indexed keywords

DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; LEVONORGESTREL; MESTRANOL; NORETHISTERONE; NORETYNODREL; NORGESTRIENONE; ORAL CONTRACEPTIVE AGENT;

BLOOD CLOTTING; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; DRUG SAFETY; HEART INFARCTION; HUMAN; INCIDENCE; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; SHORT SURVEY; SMOKING;

CONTRACEPTIVES, ORAL, COMBINED; FEMALE; HUMANS; INCIDENCE; MYOCARDIAL INFARCTION; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGESTINS; RISK ASSESSMENT; RISK FACTORS;

EID: 0141924502     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/07853890310001267     Document Type: Short Survey

References (47)

1. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986; 111: 383-90.
2. Cassel JC. Summary of major findings of the Evans County cardiovascular studies. Arch Intern Med 1971; 128: 887-9.
3. McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H, et al. Recent trends in acute coronary heart disease-mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. N Engl J Med 1996; 334: 884-90.
4. Petitti DB, Sidney S, Quesenberry CP, Jr, Bernstein A. Incidence of stroke and myocardial infarction in women of reproductive age. Stroke 1997; 28: 280-3.
5. Liese AD, Hense HW, Brenner H, Lowel H, Keil U. Assessing the impact of classical risk factors on myocardial infarction by rate advancement periods. Am J Epidemiol 2000; 152: 884-8.
6. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
7. McKenna WJ, Chew CY, Oakley CM. Myocardial infarction with normal coronary angiogram. Possible mechanism of smoking risk in coronary artery disease. Br Heart J 1980; 43: 493-8.
8. Kanitz MG, Giovannucci SJ, Jones JS, Mott M. Myocardial infarction in young adults: risk factors and clinical features. J Emerg Med 1996; 14: 139-45.
9. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
10. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99: 999-1004.
11. Ardissino D, Mannucci PM, Merlini PA, Duca F, Fetiveau R, Tagliabue L, et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94: 46-51.
12. Ardissino D, Peyvandi F, Merlini PA, Colombi E, Mannucci PM, Factor V. (Arg 506->Gln) mutation in young survivors of myocardial infarction. Thromb Haemost 1996; 75: 701-2.
13. Cushman M, Rosendaal FR, Psaty BM, Cook EF, Valliere J, Kuller LH, et al. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost 1998; 79: 912-5.
14. Dunn ST, Roberts CR, Schechter E, Moore WE, Lee ET, Eichner JE. Role of factor V Leiden mutation in patients with angiographically demonstrated coronary artery disease. Thromb Res 1998; 91: 91-9.
15. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 1037-41.
16. Franco RF, Trip MD, ten Cate H, van den Ende A, Prins MH, Kastelein JJ, et al. The 20210 G->A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol 1999; 104: 50-4.
17. Mansourati J, Da Costa A, Munier S, Mercier B, Tardy B, Ferec C, et al. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 2000; 83: 822-5.
18. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT, Jr., et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-21.
19. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90: 1747-50.
20. Amowitz LL, Komaroff AL, Miletich JP, Ridker PM, Factor V. Leiden is not a risk factor for myocardial infarction among young women. Blood 1999; 93: 1432-3.
21. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 2001; 86: 112-23.
22. Boyce J, Fawcett JW, Noall EWP. Coronary thrombosis and Conovid. Lancet 1963; i: 111.
23. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1998; 877: i-vii, 1-89.
24. Sidney S, Petitti DB, Quesenberry CP, Jr, Klatsky AL, Ziel HK, Wolf S. Myocardial infarction in users of low-dose oral contraceptives. Obstet Gynecol 1996; 88: 939-44.
25. Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1988; 319: 1313-7.
26. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. BMJ 1989; 298: 165-8.
27. Lewis MA, Heinemann LA, Spitzer WO, MacRae KD, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 1997; 56: 129-40.
28. Mant D, Villard-Mackintosh L, Vessey MP, Yeates D. Myocardial infarction and angina pectoris in young women. J Epidemiol Community Health 1987; 41: 215-9.
29. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1997; 349: 1202-9.
30. D'Avanzo B, La Vecchia C, Negri E, Parazzini F, Franceschi S. Oral contraceptive use and risk of myocardial infarction: an Italian case-control study. J Epidemiol Community Health 1994; 48: 324-5.
31. Rosenberg L, Palmer JR, Lesko SM, Shapiro S. Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol 1990; 131: 1009-16.
32. Thorogood M, Mann J, Murphy M, Vessey M. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study. Br J Obstet Gynaecol 1991; 98: 1245-53.
33. Sidney S, Siscovick DS, Petitti DB, Schwartz SM, Quesenberry CP, Psaty BM, et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation 1998; 98: 1058-63.
34. Rosenberg L, Palmer JR, Rao RS, Shapiro S. Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med 2001; 161: 1065-70.
35. Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345: 1787-93.
36. Dunn N, Thorogood M, Faragher B, de Caestecker L, MacDonald TM, McCollum C, et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 1999; 318: 1579-83.
37. Jick H, Jick S, Myers MW, Vasilakis C. Risk of acute myocardial infarction and low-dose combined oral contraceptives. Lancet 1996; 347: 627-8.
38. Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315-26.
39. Rosing J, Tans G, Nicolaes G, Thomassen M, van OR, van dPP, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
40. Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-40.
41. Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84: 15-21.
42. Middeldorp S, Meijers JC, van den Ende AE, van Enk A, Bouma BN, Tans G, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84: 4-8.
43. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
44. Ma J, Hennekens CH, Ridker PM, Stampfer MJ. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. J Am Coll Cardiol 1999; 33: 1347-52.
45. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236-40.
46. Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001; 85: 584-95.
47. Crook D, Godsland I. Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism. Contraception 1998; 57: 189-201.